PHARMACEUTICAL 2012

Nektar Therapeutics
Rank 123 of 196

NEKTAR



PHARMACEUTICAL 2012

Nektar Therapeutics
Rank 123 of 196

The relative strengths and weaknesses of Nektar Therapeutics are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Nektar Therapeutics compared to the market average is the variable Assets, increasing the Economic Capital Ratio by 55% points.The greatest weakness of Nektar Therapeutics is the variable Liabilities, reducing the Economic Capital Ratio by 97% points.

The company's Economic Capital Ratio, given in the ranking table, is 196%, being 38% points below the market average of 234%.

Input Variable	Value in 1000 USD
Assets, Current	276,706
Cost of Goods Sold	0
Intangible Assets	76,501
Liabilities, Current	275,532
Liabilities, Non-Current	7,159
Other Assets	174,767
Other Compr. Net Income	0
Other Expenses	22,909
Other Liabilities	126,048
Other Net Income	-9,023
Other Revenues	71,480
Property and Equipment	78,576
Research and Development	126,766
Selling, General and Administrative Expense	46,760

Output Variable	Value in 1000 USD
Assets	606,550
Liabilities	408,739
Expenses	196,435
Revenues	71,480
Stockholders Equity	197,811
Net Income	-133,978
Comprehensive Net Income	-133,978
BaseVar	646,114
ECR before LimitedLiability	59%
Economic Capital Ratio	196%